BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TBF Tissue Engineering Celebrates 20 Years of Clinical Use of the PHOENIX® Cancellous Bone Treatment Process


9/4/2012 11:58:00 AM

Mions (I-Newswire) August 31, 2012 - TBF Tissue Engineering, a leading provider of orthopedic cancellous bone allografts from live donors only, is celebrating 20 years of sterilizing human allografts through the PHOENIX® process. Since the first clinical use in 1992, there has been no incidence of allograft associated infections from more than the 100,000 grafts implanted.

The PHOENIX® process is a highly advanced technical cleaning process designed and developed by TBF Tissue Engineering, France to sterilize and preserve bone tissue for implantation. The end-product is secured, freeze-dried and packaged for a 5-yr shelf life storage at room temperature. PHOENIX® Products have been duely authorized by the Affsaps - now ANMS - (French MOH authorities) and is fully compliant with most restrictive European directives on Human Tissues. The cancellous bone allografts produced through the PHOENIX® Process are mostly used in dental, orthopedic, spinal, neuro, trauma and oncology surgery.

“Besides, the ethical foundations of working only with live donors, we are extremely proud of our history of PHOENIX®-secured implants, which fully meet our mission statement, ie. guarantee patients and surgeons utmost quality products with maximum safety.” said Dr. Laurence BARNOUIN, General Manager of TBF. “Providing efficient, easy to use and safe products is indeed a top priority for our company.”

Given the obvious benefits in terms of safety (ie. non-contamination) and traceability of working with living donors, in addition to the thoroughness of its cleaning process, TBF has been proud to provide surgeons worldwide a fast, reliable and durable solution for osteoconduction (hence osteoconstruction) since 1992 through its 100% mineralized cancellous-only bone allografts.

About TBF:

TBF Tissue Engineering (also known as Tissue Bank of France) is a well-established innovative biotechnology company, created in 1992, which focuses on advanced Tissue Engineering on human material, exclusively from living donors. TBF is today a leading provider of Secured freeze-dried cancellous bone allografts for bone-void filling and reconstruction. TBF is also an R&D structure working on human tissues (eg. meniscus, ...), a Pharmaceutical establishment manufacturing medicinal cell therapy products (eg. chondrocytes implants), a GMP partner offering CMO services for advanced medicinal therapy products (any development stage).

TBF markets include mainly Orthopaedic, Neuro, Spine, Trauma and Dental surgery.

Company Contact Information

TBF

Vincent JACQUES

6 rue d'Italie

69780 Mions - France

69780

Phone : +33 (0)472 68 69 02



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES